Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17613351 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | Final Rejection | Novartis AG |
| 17753850 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | Final Rejection | NOVARTIS AG |
| 17783939 | MYELOID CELL-TARGETED NANOPARTICLES AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17616916 | MODULATION OF ORAL MICROBIOTA | Non-Final OA | MARS, INCORPORATED |
| 18032760 | PROINFLAMMATORY PRODRUGS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17769960 | ASSAY FOR RAPID EVALUATION OF CHOROIDAL MAST CELL DEGRANULATION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17618944 | PHOTOACTIVE COMPOSITIONS FOR THERAPUETIC AGENT DELIVERY | Final Rejection | The University of North Carolina at Chapel Hill |
| 18119456 | FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT | Non-Final OA | TDK Corporation |
| 18304987 | USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA | Non-Final OA | FUDAN UNIVERSITY |
| 18002681 | COMPOSITIONS AND METHODS OF USING A PLA2-RESPONSIVE DRUG DELIVERY SYSTEM | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17604305 | COMPOUNDS AND METHODS FOR IMAGING IMMUNE ACTIVITY | Final Rejection | Board of Regents, The University of Texas System |
| 17762279 | TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER | Non-Final OA | SEIKAGAKU CORPORATION |
| 17910248 | TARGETED NANOBUBBLE THERAPY | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 17782369 | COMPOSITIONS AND METHODS FOR TUNABLE MAGNETIC NANOPARTICLES | Non-Final OA | The General Hospital Corporation |
| 17796494 | HIGH MOLECULAR WEIGHT HEPARIN COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING AND MONITORING EOSINOPHIL MEDIATED INFLAMMATORY DISEASES | Non-Final OA | University of Utah Research Foundation |
| 17007994 | CONJUGATED POLYCATIONIC POLYMERS, METHODS OF USING THE SAME AND METHODS OF TREATING AUTOIMMUNE DISEASES, INFECTIOUS DISEASES AND ACUTE RADIATION EXPOSURE | Final Rejection | Duke University |
| 18015807 | ASYMMETRIC CHARGED VESICLES AND METHODS OF PREPARING AND USE THEREOF | Final Rejection | The Research Foundation for the State University of New York |
| 17422052 | METHOD FOR SYNTHESIZING HYALURONIC ACID NANOPARTICLES, AND HYALURONIC ACID NANOPARTICLES PREPARED BY METHOD | Non-Final OA | Kyungpook National University Industry-Academic Cooperation Foundation |
| 18044444 | STABILIZED HYDROPHOBIC NANOPARTICLES FOR ULTRASOUND IMAGING | Non-Final OA | Oregon Health & Science University |
| 18002761 | OXINE-CONTAINING CELL RADIOLABELLING AGENTS | Final Rejection | KING'S COLLEGE LONDON |
| 17995024 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Non-Final OA | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION |
| 18004099 | DEUTERATED AND TRITIATED N-(4,5-DIMETHYLTHIAZOLO-2(3H)-YLIDEN)-2,2,3,3-TETRAMETHYLCYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF | Non-Final OA | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. |
| 17641787 | ANTI-NUCLEOLIN AGENT-PEG-CONJUGATED NANOPARTICLES | Final Rejection | University of Louisville Research Foundation, Inc. |
| 17622580 | TRANSFECTION METHOD | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17635409 | LARGE SCALE PRODUCTION OF EXOSOME MIMETICS AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 17634897 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | Non-Final OA | LONZA SALES AG |
| 18249192 | PNA PROBES FOR PRETARGETED IMAGING AND THERAPY | Non-Final OA | Zytox Therapeutics AB |
| 18182076 | REACTIONS OF RADIOACTIVE COMPOUNDS FACILITATED BY A SOLID PHASE | Non-Final OA | Precirix N.V. |
| 17923314 | HYDROGEL IRRADIATION | Non-Final OA | Ascendis Pharma A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy